Synergetic insulin sensitizing effect of rimonabant and BGP-15 in zucker-obes rats

Zsuzsanna Literati-Nagy, Kálmán Tory, Botond Literáti-Nagy, Ágnes Bajza, László Vígh, László Vígh, József Mandl, Zoltán Szilvássy

Research output: Contribution to journalArticle

3 Citations (Scopus)


Abdominal obesity is referred for as a common pathogenic root of multiple risk factors, which include insulin resistance, dyslipidemia, hypertension, and a pro-atherogenic and pro-inflammatory state. Irrespective of its psychiatric side effects, rimonabant through blocking cannabinoid-1 receptor (CB1R) induces an increase in whole body insulin sensitivity. The aim of this work was to study the effect of selected doses of another insulin sensitizer compound BGP-15, and rimonabant on insulin resistance in Zucker obese rats with a promise of inducing insulin sensitization together at lower doses than would have been expected by rimonabant alone. We found that BGP-15 potentiates the insulin sensitizing effect of rimonabant. The combination at doses, which do not induce insulin sensitization by themselves, improved insulin signaling. Furthermore our results suggest that capsaicin-induced signal may play a role in insulin sensitizing effect of both molecules. Our data might indicate that a lower dose of rimonabant in the treatment of insulin resistance and type 2 diabetes is sufficient to administer, thus a lower incidence of the unfavorable psychiatric side effects of rimonabant are to be expected.

Original languageEnglish
Pages (from-to)571-575
Number of pages5
JournalPathology and Oncology Research
Issue number3
Publication statusPublished - Jul 1 2013


  • BGP-15
  • Capsaicin
  • Glucose clamp
  • Insulin resistance
  • Obesity
  • Rimonabant

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Synergetic insulin sensitizing effect of rimonabant and BGP-15 in zucker-obes rats'. Together they form a unique fingerprint.

  • Cite this